Olamkicept (FE-301) is a soluble gp130-Fc-fusion protein that selectively inhibits interleukin 6 (IL-6) trans-signaling by binding to the soluble IL-6 receptor/IL-6 complex.

Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers.

Tebentafusp (IMCgp100) is a protein that specifically targets gp100 and consists of a soluble T-cell receptor functionally fused to an anti-CD3 immune effector Tebentafusp has potential anti-tumor activity, induces the production of inflammatory cytokines and cytolytic proteins, and can be used to study unresectable or metastatic uveal melanoma.

Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.[1]

Inbakicept is a dimer of IL-15 receptor alpha sushi domain and immunoglobulin G1 (human Fc fragment) fusion protein, which is an IL-15 super agonist protein complex. Inbakicept binds to IL-15 antibody Nogapendekin alfa to form the complex Nogapendekin alfa inbakicept (ALT-803) in a 1:2 ratio. ALT-803 has potential anticancer and anti-tumor activities, which can be used to study breast cancer.

Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B-cell stimulation by binding to B-lymphocyte stimulatory factors and proliferation-inducing ligands, and can be used in the study of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and various B-cell malignancies.

Nemvaleukin alfa (ALKS 4230) is an interleukin 2 fusion protein, a selective agonist of the medium-affinity IL-2 receptor, produced by fusion of the IL-2Ralpha subunit of the circularly arranged interleukin-2 (IL-2) and IL-2 receptor (IL-2R) complexes, which drives antitumor Immunity and inhibits tumor growth in small cell lung cancer.

Baminercept (BG 9924) is a lymphotoxin-β receptor-immunoglobulin fusion protein that blocks the lymphotoxin-alphabets/LIGHT axis, and is used to study primary desiccation syndrome (SS) with rheumatoid arthritis (RA).

Simlukafusp alfa (FAP-IL2v) is a tumor-targeting immune cytokine, a human IgG1 antibody, with antitumor activity and immunostimulatory properties that potentiate in vitro and in vivo activity of therapeutic antibodies mediating antibody-dependent or T-cell-independent cytotoxicity (TDCC) and programmed death ligand 1 (PD-L1) checkpoint inhibition.

Sotatercept (ACE-011) is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein and inhibitor of activin signaling.Sotatercept can be used in the study of pulmonary arterial hypertension.

Bintrafusp alfa (M7824) is a bifunctional fusion protein consisting of the extracellular structural domain of TGF-βRII (a TGF-β "trap") fused to a monoclonal antibody against human immunoglobulin G1 fused to programmed death ligand 1 (PD-L1), which is known for its anticancer activity, and can be used to study esophageal cancer. It has anticancer activity and can be used to study esophageal cancer.

Ipafricept (OMP-54F28) is a recombinant fusion protein consisting of the extracellular portion of the human frizzled-8 receptor fused to a fragment of human IgG1 Fc, and a Wnt inhibitor that blocks Wnt signaling.Ipafricept is a decoy receptor for Wnt ligands and has anticancer activity, and may be useful in the study of solid tumors.

Insulin efsitora alfa (LY-3209590) is a selective insulin receptor (IR) agonist and fusion protein that combines a novel single-chain insulin variant with the structural domain of human IgG Fc for the study of type 2 diabetes.

Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.Latikafusp initiates and prolongs cytotoxicity and memory T-cell activity and induces the generation of immunogenicity-mediated responses.

COVA208 is a bispecific FynomAb targeting HER2, consisting of a fusion protein of an antibody and a FynSH3-derived binding protein. It induces the degradation of HER2, reducing the levels of HER2, HER3, and EGFR, effectively blocking downstream signaling pathways such as HER3-PI3K-AKT and MAPK, and inducing apoptosis in tumor cells. COVA208 shows promise for research in cancers like HER2-positive breast, gastric, and colorectal cancers.

Balekafusp alfa is a human IgG1κ antibody targeting IL-2, known for its antitumor properties.

RO7122290 is a bispecific antibody-like fusion protein composed of a trimeric ligand for the T-cell co-stimulatory receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulatory and antitumor activities. It shows promise in the treatment of advanced solid tumors. Molecular weight: 177.78 KD.

Efranarelaxin alfa is an agonist of the relaxin receptor. It shows potential for research in cardiovascular diseases and tissue repair.

Redalsomatropin alfa is a humanized antibody targeting the GHR (Growth Hormone Receptor).

Ebribafusp alfa is a chimeric IgG4κ antibody that targets CD3E, with its corresponding isotype control designated as Human IgG4(S228P) kappa, Isotype Control.

Timdarpacept (IMM01) is a recombinant SIRPa-Fc fusion protein that enhances antitumor activity by blocking the CD47-SIRPa interaction and activating macrophages.

Lucorafusp alfa is a humanized IgG4κ antibody targeting TIGIT; its corresponding isotype control is HumanIgG4(S228P) kappa, Isotype Control.

Amulirafusp alfa is a humanized IgG1κ antibody targeting MS4A1/CD47, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.

Gulgafafusp alfa is a human IgG2κ monoclonal antibody that selectively binds to the glucagon-like peptide 1 receptor (GLP1R) [1].